Trial Profile
A phase I/II study to evaluate the safety, tolerance and efficacy of RSR13 (efaproxiral) administered to patients receiving a course of cisplatin and radiation therapy for locally advanced carcinoma of the cervix
Status:
Not stated
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2006
Price :
$35
*
At a glance
- Drugs Efaproxiral (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Therapeutic Use
- 20 Feb 2006 New trial record.